A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).

A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol. 2010 Mar; 5(3):380-4.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Agents
Dasatinib
Drug Resistance, Neoplasm
Female
Humans
Lung Neoplasms
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Protein Kinase Inhibitors
Pyrimidines
Salvage Therapy
Small Cell Lung Carcinoma
Survival Rate
Thiazoles
Treatment Outcome
Young Adult

authors with profiles

Everett E. Vokes